This is a double-blind, placebo-controlled, randomized, multi-center study. Subjects agreeing
to participate in the study and meet the entry criteria assessed at the screening visit, will
begin a 28 day baseline period to confirm their diagnosis, as well as establish baseline
migraine characteristics. During this baseline period, subjects will continue treating their
migraines as usual, simply recording the information in a daily headache diary. Subjects who,
after completing the baseline, continue to meet entrance criteria will be eligible to enter
into the treatment phase and be randomized according to the Clinvest generated randomization
schedule. Approximately 142 subjects (71 subjects per arm) will be randomized and enter the
treatment phase receiving MLD10 or placebo in a 1:1 design at 6 United States sites. Diary
assessments will collect study medication adherence, pain severity, headache symptoms, acute
medication usage, and unusual symptoms. Serum samples will be collected and analyzed for
ionized magnesium, electrolytes, and creatinine.